Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
- PMID: 19228947
- PMCID: PMC2656196
- DOI: 10.1073/pnas.0811698106
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
Abstract
Synapse loss correlates with a cognitive decline in Alzheimer's disease (AD), but whether this is caused by fibrillar deposits known as senile plaques or soluble oligomeric forms of amyloid beta (Abeta) is controversial. By using array tomography, a technique that combines ultrathin sectioning of tissue with immunofluorescence, allowing precise quantification of small structures, such as synapses, we have tested the hypothesis that oligomeric Abeta surrounding plaques contributes to synapse loss in a mouse model of AD. We find that senile plaques are surrounded by a halo of oligomeric Abeta. Analysis of >14,000 synapses (represented by PSD95-stained excitatory synapses) shows that there is a 60% loss of excitatory synapses in the halo of oligomeric Abeta surrounding plaques and that the density increases to reach almost control levels in volumes further than 50 microm from a plaque in an approximately linear fashion (linear regression, r(2) = 0.9; P < 0.0001). Further, in transgenic cortex, microdeposits of oligomeric Abeta associate with a subset of excitatory synapses, which are significantly smaller than those not in contact with oligomeric Abeta. The proportion of excitatory synapses associated with Abeta correlates with decreasing density (correlation, -0.588; P < 0.0001). These data show that senile plaques are a potential reservoir of oligomeric Abeta, which colocalizes with the postsynaptic density and is associated with spine collapse, reconciling the apparently competing schools of thought of "plaque" vs. "oligomeric Abeta" as the synaptotoxic species in the brain of AD patients.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Non-Fibrillar Oligomeric Amyloid-β within Synapses.J Alzheimers Dis. 2016 May 30;53(3):787-800. doi: 10.3233/JAD-160007. J Alzheimers Dis. 2016. PMID: 27258414
-
Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.Eur J Neurosci. 2016 Dec;44(12):3056-3066. doi: 10.1111/ejn.13442. Epub 2016 Nov 12. Eur J Neurosci. 2016. PMID: 27748574 Free PMC article.
-
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.Brain. 2012 Jul;135(Pt 7):2155-68. doi: 10.1093/brain/aws127. Epub 2012 May 26. Brain. 2012. PMID: 22637583 Free PMC article.
-
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease.J Cell Mol Med. 2008 Oct;12(5B):1848-62. doi: 10.1111/j.1582-4934.2008.00411.x. Epub 2008 Jul 10. J Cell Mol Med. 2008. PMID: 18624777 Free PMC article. Review.
-
[Involvement of beta-amyloid in the etiology of Alzheimer's disease].Brain Nerve. 2010 Jul;62(7):691-9. Brain Nerve. 2010. PMID: 20675873 Review. Japanese.
Cited by
-
Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases.Mol Neurodegener. 2024 Feb 20;19(1):20. doi: 10.1186/s13024-023-00651-2. Mol Neurodegener. 2024. PMID: 38378578 Free PMC article. Review.
-
Inhibition of amyloid-β(16-22) aggregation by polyphenols using replica permutation with solute tempering molecular dynamics simulation.Biophys Physicobiol. 2023 Dec 9;20(4):e200045. doi: 10.2142/biophysico.bppb-v20.0045. eCollection 2023. Biophys Physicobiol. 2023. PMID: 38344035 Free PMC article.
-
Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion.Acta Neuropathol Commun. 2024 Feb 5;12(1):22. doi: 10.1186/s40478-024-01734-x. Acta Neuropathol Commun. 2024. PMID: 38317196 Free PMC article.
-
Antibodies Raised Against an Aβ Oligomer Mimic Recognize Pathological Features in Alzheimer's Disease and Associated Amyloid-Disease Brain Tissue.ACS Cent Sci. 2023 Dec 21;10(1):104-121. doi: 10.1021/acscentsci.3c00592. eCollection 2024 Jan 24. ACS Cent Sci. 2023. PMID: 38292607 Free PMC article.
-
Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer's disease.Mol Neurodegener. 2024 Jan 18;19(1):6. doi: 10.1186/s13024-024-00702-2. Mol Neurodegener. 2024. PMID: 38238819 Free PMC article.
References
-
- Terry RD, et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572–580. - PubMed
-
- DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration. 1996;5:417–421. - PubMed
-
- Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging. 2003;24:1023–1027. - PubMed
-
- Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci. 2005;8:1051–1058. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
